| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6242412 | Respiratory Medicine | 2013 | 7 Pages |
Abstract
It was found that maintaining controlled patients on high dose FP/S is not cost-effective. Extrafine BDP/F 400/24 μg daily can be considered to be a cost-effective option in the countries analyzed to maintain control of asthmatic patients stepped down from high dose FP/S 1000/100 μg daily dry powder or suspension formulations.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Pierluigi Paggiaro, Shishir Patel, Gabriele Nicolini, Lorenzo Pradelli, Orietta Zaniolo, Alberto Papi,